Featured

Status

Health Topics

Any Category
Diseases
Clear Filters

Search Clinical Trials

215 Results
Withdrawn
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
When the patient enrolls on this study, they will be assigned a dose of CD30 chimeric receptor-activated T cells. The dose level of cells that they will receive will not …
Baylor Role: Collaborator
Completed
Pancreas Resection With and Without Drains
The rate of pancreatic fistula after pancreas resection is about 10% and surgeons have traditionally placed drains near the pancreatic anastomosis to control this potentially very serious complication. In recent …
Baylor Role: Lead Sponsor
Active, Not Recruiting
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
The EBV CTLs will be made for specific patients. First blood will be collected from the patient and then the the CD30 chimeric-EBV CTLs will be created in the lab. …
Baylor Role: Lead Sponsor
Terminated
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Everolimus has significantly improved outcomes following prior therapy. This study is a biomarker driven Phase II trial that will assess the activity of everolimus as first-line therapy for renal cell …
Terminated
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
To generate CMV-T cells we put a specially produced carrier virus (adenovirus) that carries one CMV gene into the patient's blood monocytes or dendritic cells. These cells are then used …
Baylor Role: Lead Sponsor
Withdrawn
Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies
After the eligible criterion for treatment has been met and a suitable UCB stem donor has been found, the patient will have a central line placed. Research Therapy: After placement …
Baylor Role: Lead Sponsor
Completed
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
The following will be given as the conditioning regimen for the transplant: BUSULFAN: Busulfan (intravenous BUSULFEX) dosing will be as follows: patients <12 kg: 1.1 mg/kg/dose IV every 6 hours …
Baylor Role: Lead Sponsor
Completed
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
When the patient enrolls on this study, they will be assigned to a dose of HER2-CAR CMV-T cells. The patient will be given a single injection of cells into the …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator
Active, Not Recruiting
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
WHAT IS THE OVERALL TREATMENT PLAN AND HOW MANY VACCINATIONS WILL THE PATIENT RECEIVE? There will be several injections of the vaccine scheduled. The first injection will be given 3 …
Baylor Role: Lead Sponsor